Last reviewed · How we verify
BIO-11006 Inhalation Solution
At a glance
| Generic name | BIO-11006 Inhalation Solution |
|---|---|
| Sponsor | BioMarck Pharmaceuticals, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases (PHASE2)
- Evaluation of Safety & Efficacy of BIO-11006 Inhalation Solution in Patients With ARDS (PHASE2)
- Effectiveness and Safety of BIO-11006 Inhalation Solution to Treat the Overproduction of Mucus and Inflammation in COPD (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BIO-11006 Inhalation Solution CI brief — competitive landscape report
- BIO-11006 Inhalation Solution updates RSS · CI watch RSS
- BioMarck Pharmaceuticals, Ltd. portfolio CI